Navigation Links
Denosumab Reduces Bone Erosion

According to results of a 227 patient Phase 2 trial presented at EULAR 2007, the Annual Treatment with denosumab 60 mg and 180 mg (with background methotrexate) reduces the progression of bone erosion .

Denosumab is a fully human monoclonal antibody which binds to and inhibits the RANK Ligand. The RANK Ligand is the essential mediator of osteoclast formation, function, and survival and thereby plays a key role in rheumatoid arthritis (RA) associated bone erosions (osteoclasts are the cells responsible for the break down of bone material).

Bone status in patients hands and feet was assessed by radiographs at initiation of trial, six and 12 months to assess the capacity of denosumab to reduce progression of RA associated bone erosion. Researchers gathered data on erosion score (a measure of damage to joints), joint space narrowing (a measure of reduced space between bones in each joint) and derived the van der Heijde modified Total Sharp Score (TSS)

Professor Desiree van der Heijde of Leiden University Medical Center and lead author of the study commented, These data show the significant potential of denosumab, revealing that patients receiving denosumab experienced a reduced progression of erosions compared to control. Most significant was the difference observed between the control group and the group receiving denosumab 180mg. The reduction in progression of erosions was already present in this group as early as 6 months.

In the double-blind, placebo-controlled, phase 2 study, 227 patients were randomly assigned to receive subcutaneous denosumab injections or placebo at initiation of trial, and after six months, to determine if denosumab could reduce the progression of bone erosions in patients with RA on background methotrexate (MTX standard RA treatment).

Mean erosion scores were significantly reduced for the groups treated with denosumab compared to the control group. Change in mean erosion score at 12 months was reported as 0.33 and 0.19 for treatment with denosumab 60 mg and 180 mg respectively, compared with the change in score for the control group of 1.34 (respective p= 0.01 and p= 0.007).

For the 180mg group the reduction in progression in erosions was already significantly less as compared to the control group after 6 months (0.05 vs. 0.59, p-value = 0.02) and a trend was seen in the 60 mg group (0.25).

An increase in TSS was observed in the control group of patients at 12 months, significantly higher than that observed in patients in the treatment groups. For patients receiving denosumab, the progression in TSS at 12 months was 0.85 and 0.97 for denosumab 60mg and 180mg respectively as compared to 1.87 for the control group (respectively, p=0.03 and p=0.18).

No specific differences in the in Joint Space Narrowing (JSN) were detected between the denosumab and the control groups.In this study, safety was continually monitored and an adverse event profile similar to that of patients receiving placebo was observed in patients receiving treatment with denosumab.


'"/>




Related medicine news :

1. Drug Reduces Risk of Clogged Arteries, Veins
2. Sunshine Reduces MS Risk
3. Estrogen in Food Reduces Cancer Risk
4. Dental Procedure Reduces Preterm Births
5. Vaccine Reduces antibiotic-resistant infections in Children
6. Eating Fiber Reduces The Risk Of Heart Disease
7. Higher Statin Dose Safely Reduces Stroke and Cardiac Arrest
8. Anti-tobacco Advertising Can Reduces smoking Among Teens
9. Eating Fish Reduces Heart Disease
10. Co-trimoxazole Use Reduces Childhood AIDS –Related Death
11. NSAIDS, Reduces The Risk Of Oral Cancer But Causes Heart Attacks
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from PsychTests.com reveals that behind the tendency to ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... ... ... recruitment firm Slone Partners is pleased to announce the placement of Suzanne ... of North American Capital Sales at HTG Molecular . , In ... commercialization of the HTG EdgeSeq system and associated reagents in North America. , Headquartered ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... startling report released today, National Safety Council research shows ... plan to eliminate prescription opioid overdoses. Prescription Nation ... the worst drug crisis in recorded U.S. history, assigned a "Making ... , New Mexico , Tennessee ... states, three – Michigan , Missouri ...
Breaking Medicine Technology: